NewsRx

Search our medical news database

BioRx

BioRx Offers Berinert (R) to Patients with Hereditary Angioedema

Published in Medical Letter on the CDC and FDA, January 3rd, 2010

BioRx, a specialty pharmacy company, has been named one of a small number of approved providers of Berinert®. Berinert® is a plasma-derived concentrate of C1 esterase inhibitor (human) indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients. CSL Behring, the manufacturer of Berinert® selected BioRx as part of their distribution network to launch this exciting new product in the United States.

BioRx will be launching a dedicated website, www.haefreedom.com, to provide information about HAE, treatment options, and related BioRx services.

HAE is a very rare,...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook